Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-09-12

Clinical Trial Update: A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating BI 1015550 for improving lung function in idiopathic pulmonary fibrosis has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BI-1015550 (BI-1015550)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Idiopathic Pulmonary Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2025-09-12